|By Marketwired .||
|April 11, 2014 07:00 AM EDT||
MOUNTAIN VIEW, CA--(Marketwired - April 11, 2014) - VIVUS (NASDAQ: VVUS) today announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology (EAU) Congress at Stockholmsmässan in Stockholm, Sweden.
About the Study
Authors: Hartmut Porst, Ian Eardley, Dimitrios Hatzichristou, Craig Peterson, Winnie Shih
Title: "Use of Avanafil and Successful Intercourse Within Approximately 15 Minutes of Dosing in Men With Mild to Severe Erectile Dysfunction"
About the Presentation
Session Title: Men's sexual health: Treatment of erectile dysfunction
Session Type: Poster Session 49
Presentation Type: Standard
Date: Sunday, 13 April 2014, 14:00 to 15:30
Room: Room T1
STENDRA™ (avanafil) is approved by the FDA in the U.S. for the treatment of erectile dysfunction. STENDRA is rapidly absorbed and should be taken 30 minutes before sexual activity on an as-needed basis. STENDRA should not be taken more than once per day and may be taken without regard to food and with modest alcohol consumption.
VIVUS has granted Auxilium Pharmaceuticals, Inc. exclusive marketing rights to STENDRA in the U.S. and Canada; Auxilium is in the early stages of commercializing STENDRA in the U.S.
SPEDRA™, the trade name for avanafil in the European Union (EU), is approved by the European Medicines Agency (EMA) for the treatment of erectile dysfunction in the EU.
VIVUS has granted an exclusive license to the Menarini Group through its subsidiary Berlin-Chemie AG to commercialize and promote SPEDRA for the treatment of erectile dysfunction in over 40 European countries plus Australia and New Zealand.
VIVUS has granted an exclusive license to Sanofi to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.
Avanafil is licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. VIVUS is in discussions with other parties for the commercialization rights to its remaining territories.
For more information about STENDRA, please visit www.STENDRA.com.
Important Safety Information
STENDRA™ (avanafil) is prescribed to treat erectile dysfunction (ED).
Do not take STENDRA if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure.
Discuss your general health status with your healthcare provider to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.
STENDRA may affect the way other medicines work. Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir
In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including STENDRA) reported a sudden decrease or loss of vision. It is not possible to determine whether these events are related directly to these medicines or to other factors. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including STENDRA, and call a doctor right away.
Sudden decrease or loss of hearing has been rarely reported in people taking PDE5 inhibitors, including STENDRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you experience sudden decrease or loss of hearing, stop taking STENDRA and contact a doctor right away. If you have prostate problems or high blood pressure for which you take medicines called alpha blockers or other anti-hypertensives, your doctor may start you on a lower dose of STENDRA.
Drinking too much alcohol when taking STENDRA may lead to headache, dizziness, and lower blood pressure.
STENDRA in combination with other treatments for ED is not recommended.
STENDRA does not protect against sexually transmitted diseases, including HIV.
The most common side effects of STENDRA are headache, flushing, runny nose and congestion.
Please see full patient prescribing information for STENDRA (50 mg, 100 mg, 200 mg) tablets.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate", "believe", "forecast", "estimate", "expect", "intend", "likely", "may", "plan", "potential", "predict", "opportunity" and "should", among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in the VIVUS Form 10-K for the year ending December 31, 2013, and periodic reports filed with the Securities and Exchange Commission.
Dec. 8, 2016 08:30 PM EST Reads: 1,880
Dec. 8, 2016 07:45 PM EST Reads: 299
Dec. 8, 2016 07:15 PM EST Reads: 353
Dec. 8, 2016 06:45 PM EST Reads: 940
Dec. 8, 2016 05:45 PM EST Reads: 942
Dec. 8, 2016 05:45 PM EST Reads: 1,717
Dec. 8, 2016 05:00 PM EST Reads: 1,813
Dec. 8, 2016 04:45 PM EST Reads: 1,843
Dec. 8, 2016 04:45 PM EST Reads: 2,247
Dec. 8, 2016 04:30 PM EST Reads: 375
Dec. 8, 2016 04:30 PM EST Reads: 1,968
Dec. 8, 2016 04:15 PM EST Reads: 297
Dec. 8, 2016 04:15 PM EST Reads: 2,311
Dec. 8, 2016 04:00 PM EST Reads: 1,078
Dec. 8, 2016 03:45 PM EST Reads: 1,091